Drug
Azenosertib clinical trials
Also written ZN-c3 and KP-2638.
- studies test it
- 12
- open now
- 4
- in phase 3
- 1
- first study started
- 2019
Keep track of what changes. Save the azenosertib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 6
- Phase 2
- 4
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 4
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (6) · OHSU Knight Cancer Institute (2) · Joyce Liu, MD (1) · Filipa Lynce, MD (1) · K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (1) · Zentera Therapeutics HK Limited (1)
Often tested with
Tested in the same studies.
Gemcitabine (1) · Cobimetinib (1) · Olaparib (1) · Onvansertib (1) · AZD5305 (1) · Tremelimumab (1) · Carboplatin (1) · Pembrolizumab (1)
Studies
Open first, then newest update. How each study uses azenosertib is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerRecruitingPhase 2K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT05128825Written as azenosertib
- Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingEarly Phase 1OHSU Knight Cancer InstituteNCT04005690Written as Azenosertib
- A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein ExpressionRecruitingPhase 3K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT07546500Written as Azenosertib
- Azenosertib in Uterine Serous Carcinoma: Biomarker StudyRecruitingPhase 2Joyce Liu, MDNCT06369155Written as Azenosertib
- ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBCTerminatedPhase 1Filipa Lynce, MDNCT06351332Written as Azenosertib
- A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With OsteosarcomaCompletedPhase 1K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT04833582Written as Azenosertib
- A Study of Azenosertib (ZN-c3) in Participants With Solid TumorsCompletedPhase 1K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT04158336Written as Azenosertib
- A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous CarcinomaCompletedPhase 2K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT04814108Written as Azenosertib
- ZN-c3 in Adult Participants With Metastatic Colorectal CancerTerminatedPhase 1K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT05743036Written as ZN-c3
- Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)TerminatedPhase 1/2K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.NCT05682170Written as ZN-c3
- ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian CancerWithdrawnEarly Phase 1OHSU Knight Cancer InstituteNCT05368506Written as Wee1 Inhibitor ZN-c3
- A Phase 1b Study of ZN-c3 in Chinese SubjectsStatus unknownPhase 1Zentera Therapeutics HK LimitedNCT04972422Written as ZN-c3
Given in every arm · 4 — azenosertib is usual care beside what is tested
- Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT06364410Written as Azenosertib
- A Study of Azenosertib (ZN-c3) in Patients With Ovarian CancerRecruitingPhase 1K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT04516447Written as Azenosertib
- A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerCompletedPhase 1/2K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT05198804Written as Azenosertib
- Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid TumorsWithdrawnPhase 1M.D. Anderson Cancer CenterNCT05431582Written as ZN-c3
Codes
What other systems call azenosertib · ClinicalTrials.gg INT015873
- UNII (FDA) 9J13XU96Z1AZENOSERTIBOne source FDA
- NCI Thesaurus C167064AzenosertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9J13XU96Z1 | AZENOSERTIB | One source FDA |
| NCI Thesaurus | C167064 | Azenosertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.